Maryland News Desk

Delveinsight Business Research LLP

“Benign Prostatic Hyperplasia (BPH) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Benign Prostatic Hyperplasia Market. 

The Benign Prostatic Hyperplasia Pipeline report embraces in-depth commercial, regulatory, and Benign Prostatic Hyperplasia clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Benign Prostatic Hyperplasia drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Benign Prostatic Hyperplasia (BPH) Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for Benign Prostatic Hyperplasia treatment and the aggregate therapies developed by major pharma companies.

• It accesses the different Benign Prostatic Hyperplasia therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the major Benign Prostatic Hyperplasia companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the Benign Prostatic Hyperplasia drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Benign Prostatic Hyperplasia therapeutic market.

Benign Prostatic Hyperplasia (BPH) Therapeutics Landscape

The Benign Prostatic Hyperplasia (BPH) treatment includes watchful waiting, medical therapies, minimally invasive surgery, and surgery. Watchful waiting is the recommended strategy for patients with BPH who have mild symptoms and for those with moderate-to-severe symptoms who are not bothered by their symptoms and are not experiencing complications of BPH.

Medical therapies for the treatment of BPH include alpha-blockers, phosphodiesterase-5 inhibitors, 5-alpha reductase inhibitors, and combination medications.

The smooth muscle tension is mediated by alpha-1-adrenergic receptors; hence, alpha-adrenergic receptor–blocking agents relax the smooth muscle, thus allowing easier passage of urine. Based on the receptor subtype selectivity and the duration of serum elimination half-lives, they are categorized into nonselective alpha-blockers (phenoxybenzamine), selective short-acting alpha-1 blockers (prazosin, alfuzosin, indoramin), selective long-acting alpha-1 blockers (terazosin, doxazosin, slow-release alfuzosin), and partially subtype (alpha-1a)–selective agents (tamsulosin (Flomax), silodosin (Rapaflo)).

The US FDA-approved alpha-blockers include terazosin (Hytrin), doxazosin (Cardura), tamsulosin (Flomax), alfuzosin (Uroxatral), and silodosin (Rapaflo). Prazosin, an older alpha-1 adrenergic blocker, is FDA-approved for use in hypertension only.

There are approx. 12+ key companies developing therapies for Benign Prostatic Hyperplasia (BPH).  Currently, Nymox Pharmaceutical is leading the therapeutics market with its Benign Prostatic Hyperplasia (BPH) drug candidates in the most advanced stage of clinical development. Vibegron (Urovant Sciences) and DKF-313 (Dongkook Pharmaceutical) are the most anticipated emerging therapies, awaiting approval. Another emerging drug AUS-131 (Ausio Pharmaceuticals) was evaluated in phase II clinical trial.

Benign Prostatic Hyperplasia Companies Actively Working in the Therapeutic Market Include:

• Nymox Pharmaceutical

• ASKA Pharmaceutical

• Otsuka Pharmaceutical

• Aiviva BioPharma

• KAEL-GemVax

• Dong-A ST/Mezzion

And Many Others

Emerging and Marketed Benign Prostatic Hyperplasia Drugs Covered in the Report Include:

• Fexapotide: Nymox Pharmaceutical

• AIV007: AiViva BioPharma

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Benign Prostatic Hyperplasia Companies Working in the Market @

https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight

Analysis of Emerging Benign Prostatic Hyperplasia Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued and inactive candidates

Route of Administration

Benign Prostatic Hyperplasia (BPH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody

• Peptides

• Small molecule

Learn How the Benign Prostatic Hyperplasia Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Benign Prostatic Hyperplasia Treatment Patterns

4. Benign Prostatic Hyperplasia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Benign Prostatic Hyperplasia Late Stage Products (Phase-III)

7. Benign Prostatic Hyperplasia Mid-Stage Products (Phase-II)

8. Benign Prostatic Hyperplasia Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Benign Prostatic Hyperplasia Discontinued Products

13. Benign Prostatic Hyperplasia Product Profiles

14. Major Benign Prostatic Hyperplasia Companies in the Market

15. Key Products in the Benign Prostatic Hyperplasia Therapeutics Segment

16. Dormant and Discontinued Products

17. Benign Prostatic Hyperplasia Unmet Needs

18. Benign Prostatic Hyperplasia Future Perspectives

19. Benign Prostatic Hyperplasia Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight 

Thymus Cancer Market

“Thymus Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Thymus Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Thymus Cancer market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices